United Kingdom Zearalenone Antibody Market Size & Outlook, 2026-2034

United Kingdom Zearalenone Antibody Market Insights

According to Deep Market Insights analysis, the United Kingdom Zearalenone Antibody Market size was USD 114.69 Million in 2025 and is projected to reach USD 469.33 Million by 2034.
The United Kingdom market is projected to grow at a CAGR of 16.99% between 2026 and 2034.
By segment, Monoclonal antibodies emerged as the largest By Type in terms of market size in 2025.
Polyclonal antibodies is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.

United Kingdom contributed 4.22% to the global Zearalenone Antibody Market size in 2025.
By 2034, United States is forecasted to remain the largest global market for Zearalenone Antibody Market.
In Europe, Germany is projected to capture the leading share of market size by 2034.
Among Europe markets, Russia is expected to post the fastest growth, reaching USD 241.2 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 114.69 Million
Market Size In 2034	USD 469.33 Million
Largest segment	Monoclonal antibodies
Units	Revenue in USD Million
CAGR	16.99% (2026-2034)
Segmnetation Covered
By Type	Monoclonal antibodies Polyclonal antibodies Recombinant antibodies Custom antibodies
By Application	Food safety testing Animal feed testing Research laboratories Diagnostic use
By Form	Liquid Lyophilized powder Conjugated antibodies Ready-to-use kits
By End User	Research institutes Food testing labs Biotech companies Academic institutions
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Monoclonal antibodies	XX.x	XX.x	XX.x	56.39	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Polyclonal antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Recombinant antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Custom antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Application	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Food safety testing	XX.x	XX.x	XX.x	53.4	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Animal feed testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Research laboratories	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Diagnostic use	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Form	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Liquid	XX.x	XX.x	XX.x	51.74	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Lyophilized powder	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Conjugated antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ready-to-use kits	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Research institutes	XX.x	XX.x	XX.x	51.7	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Food testing labs	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biotech companies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Academic institutions	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x